Antibody levels versus vaccination status in the outcome of older adults with COVID-19 DOI Creative Commons
Sylvia Mink,

Christoph H. Saely,

Andreas Leiherer

et al.

JCI Insight, Journal Year: 2024, Volume and Issue: 9(20)

Published: Oct. 22, 2024

BACKGROUNDDespite the currently prevailing, milder Omicron variant of COVID-19, older adults remain at elevated risk hospital admission, critical illness, and death. Loss efficacy immune system, including reduced strength, quality, durability antibody responses, may render generalized recommendations on booster vaccinations inadequate. There is a lack data levels in utility vaccination status versus as correlate protection. It further unclear whether be used to guide timing adults.METHODSWe conducted prospective multicenter cohort study comprising hospitalized patients with COVID-19. Anti-SARS-CoV-2 spike antibodies were measured admission. The primary endpoint was in-hospital mortality. Patients stratified by age, levels, status. Multiple logistic regression Cox analyses conducted.RESULTSIn total, 785 (≥60 years age [a]) 367 controls (<60a) included. After adjusting for confounders, mortality, ICU endotracheal intubation, oxygen administration 4.9, 2.6, 6.5, 2.3 times higher, respectively, if < 1,200 BAU/mL (aOR, 4.92 [95%CI, 2.59-9.34], P 0.0001; aOR, 2.64 1.52-4.62], = 0.0006; 6.50 1.48-28.47], 0.013; 2.34 1.60-3.343], 0.0001). Older infected approximately 6 more likely die 6.3 [95% CI, 2.43-16.40], 0.0002).CONCLUSIONAntibody stronger predictor mortality than Monitoring constitute better direct approach safeguarding from adverse COVID-19 outcomes.

Language: Английский

Antibody levels versus vaccination status in the outcome of older adults with COVID-19 DOI Creative Commons
Sylvia Mink,

Christoph H. Saely,

Andreas Leiherer

et al.

JCI Insight, Journal Year: 2024, Volume and Issue: 9(20)

Published: Oct. 22, 2024

BACKGROUNDDespite the currently prevailing, milder Omicron variant of COVID-19, older adults remain at elevated risk hospital admission, critical illness, and death. Loss efficacy immune system, including reduced strength, quality, durability antibody responses, may render generalized recommendations on booster vaccinations inadequate. There is a lack data levels in utility vaccination status versus as correlate protection. It further unclear whether be used to guide timing adults.METHODSWe conducted prospective multicenter cohort study comprising hospitalized patients with COVID-19. Anti-SARS-CoV-2 spike antibodies were measured admission. The primary endpoint was in-hospital mortality. Patients stratified by age, levels, status. Multiple logistic regression Cox analyses conducted.RESULTSIn total, 785 (≥60 years age [a]) 367 controls (<60a) included. After adjusting for confounders, mortality, ICU endotracheal intubation, oxygen administration 4.9, 2.6, 6.5, 2.3 times higher, respectively, if < 1,200 BAU/mL (aOR, 4.92 [95%CI, 2.59-9.34], P 0.0001; aOR, 2.64 1.52-4.62], = 0.0006; 6.50 1.48-28.47], 0.013; 2.34 1.60-3.343], 0.0001). Older infected approximately 6 more likely die 6.3 [95% CI, 2.43-16.40], 0.0002).CONCLUSIONAntibody stronger predictor mortality than Monitoring constitute better direct approach safeguarding from adverse COVID-19 outcomes.

Language: Английский

Citations

2